Skip to main content

Keep up to date with the latest news about Trogenix’s progress, events, and breakthroughs in cancer treatment.

Navigate to the next section
04_News & Events.

04_News & Events.

Filter Trogenix News & Events.

JP Morgan Annual Healthcare Conference 2026, San Francisco
October 21, 2025

JP Morgan Annual Healthcare Conference 2026, San Francisco

January 12-15, 2026, San Francisco.
Read More
Jefferies Healthcare Global Healthcare Conference 2025 in London
October 18, 2025

Jefferies Healthcare Global Healthcare Conference 2025 in London

November 17-20, 2025, London, UK
Read More
ICR Healthcare and Sponsors Annual Healthcare Conference 2025
October 17, 2025

ICR Healthcare and Sponsors Annual Healthcare Conference 2025

November 17, 2025, London.
Read More
2025 WFNOS & SNO Annual Meeting, Honolulu
October 17, 2025

2025 WFNOS & SNO Annual Meeting, Honolulu

19 November 2025, Honolulu.
Read More
Bio-Europe 2025
October 15, 2025

Bio-Europe 2025

November 3-5 Vienna Congress and Convention Center, Vienna, Austria
Read More
Trogenix raises £70M series A for glioblastoma gene therapy trial
October 6, 2025

Trogenix raises £70M series A for glioblastoma gene therapy trial

Newco Trogenix Ltd. has emerged from incubation and raised £70 million (US$94.1 million) in a series A, as it prepares the ground for a U.S/U.K.…
Read More
Trogenix announces £70 million / $95 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers
October 6, 2025

Trogenix announces £70 million / $95 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers

Trogenix's breakthrough Odysseus® platform targets cancer cells to deliver precision therapies with curative “one and done” potential across multiple aggressive, treatment-resistant cancers Financing round led…
Read More
Scottish biotech Trogenix raises $95M as brain cancer program nears clinic
October 5, 2025

Scottish biotech Trogenix raises $95M as brain cancer program nears clinic

Less than a year after leaving stealth mode, Trogenix has raised $95 million in a Series A round aimed at advancing its “Trojan horse” approach…
Read More
Harnessing heterogeneity to treat cancer patients
July 25, 2025

Harnessing heterogeneity to treat cancer patients

Cancer is no longer seen as a simple disease of unchecked cell growth, but as a complex, adaptive ecosystem shaped by genetic mutations, immune evasion,…
Read More
Trogenix Named Startup of the Year at Cancer Research Horizons 2025 Innovation & Entrepreneurship Awards
July 22, 2025

Trogenix Named Startup of the Year at Cancer Research Horizons 2025 Innovation & Entrepreneurship Awards

Trogenix is proud to announce its recognition as Startup of the Year at the 2025 Innovation & Entrepreneurship Awards hosted by Cancer Research Horizons, the…
Read More
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development
July 18, 2025

Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development

Atif Abbas, MD joins as CMO, bringing over 25 years’ experience in oncology drug development and clinical and regulatory strategy Carolyn Edwards, PhD appointed VP,…
Read More
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher
May 7, 2025

Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher

Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus,…
Read More
BiotechTV Tour of Scotland
March 14, 2025

BiotechTV Tour of Scotland

Edinburgh-based Trogenix is developing an AAV based gene therapy platform for cancer that is designed to deliver combination immune payloads to the tumour Amy Brown…
Read More
2024 Achievements and 2025 Outlook
December 19, 2024

2024 Achievements and 2025 Outlook

Accelerating Toward the Clinic in 2025 Trogenix has successfully achieved all milestones in platform and asset development, positioning the company to enter the clinic in…
Read More
Trogenix unveils odyssey to find one-time tumor drugs with ‘unprecedented selectivity’.
November 18, 2024

Trogenix unveils odyssey to find one-time tumor drugs with ‘unprecedented selectivity’.

Trogenix comes out of stealth, unveiling its innovative Synthetic Super-Enhancers (SSE) platform, Odysseus, to develop highly selective, one-time cancer treatments. Equipped with £15 million ($19…
Read More
Scottish biotech debuts with ‘Trojan horse’ platform for cancer
November 18, 2024

Scottish biotech debuts with ‘Trojan horse’ platform for cancer

Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate targeting an aggressive type of brain…
Read More
Trogenix unveils revolutionary platform to transform cancer treatment through precision viral immunotherapy.
November 18, 2024

Trogenix unveils revolutionary platform to transform cancer treatment through precision viral immunotherapy.

Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus,…
Read More
World-leading experts in gene therapy and brain cancer treatment convene in Edinburgh to advance Trogenix’s novel glioblastoma programme.
November 1, 2024

World-leading experts in gene therapy and brain cancer treatment convene in Edinburgh to advance Trogenix’s novel glioblastoma programme.

Trogenix recently hosted a landmark workshop at The Royal College of Surgeons in Edinburgh, uniting pioneering experts in neurosurgery, gene therapy, and oncology to advance…
Read More
Trogenix awarded Innovate UK grant to advance innovative viral immunotherapy platform for treating cancers with significant unmet medical need.
January 15, 2024

Trogenix awarded Innovate UK grant to advance innovative viral immunotherapy platform for treating cancers with significant unmet medical need.

Grant will accelerate development and evaluate Trogenix’s SSE technology in liver hepatocellular carcinoma and colorectal cancer liver metastases Edinburgh, UK, January 2024 - Trogenix Ltd…
Read More
Trogenix announces £70 million / $95 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers
October 6, 2025

Trogenix announces £70 million / $95 million Series A financing to drive clinical development of potentially curative therapies for aggressive cancers

Trogenix's breakthrough Odysseus® platform targets cancer cells to deliver precision therapies with curative “one and done” potential across multiple aggressive, treatment-resistant cancers Financing round led…
Read More
Trogenix Named Startup of the Year at Cancer Research Horizons 2025 Innovation & Entrepreneurship Awards
July 22, 2025

Trogenix Named Startup of the Year at Cancer Research Horizons 2025 Innovation & Entrepreneurship Awards

Trogenix is proud to announce its recognition as Startup of the Year at the 2025 Innovation & Entrepreneurship Awards hosted by Cancer Research Horizons, the…
Read More
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development
July 18, 2025

Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development

Atif Abbas, MD joins as CMO, bringing over 25 years’ experience in oncology drug development and clinical and regulatory strategy Carolyn Edwards, PhD appointed VP,…
Read More
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher
May 7, 2025

Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher

Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus,…
Read More
2024 Achievements and 2025 Outlook
December 19, 2024

2024 Achievements and 2025 Outlook

Accelerating Toward the Clinic in 2025 Trogenix has successfully achieved all milestones in platform and asset development, positioning the company to enter the clinic in…
Read More
Trogenix unveils revolutionary platform to transform cancer treatment through precision viral immunotherapy.
November 18, 2024

Trogenix unveils revolutionary platform to transform cancer treatment through precision viral immunotherapy.

Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus,…
Read More
World-leading experts in gene therapy and brain cancer treatment convene in Edinburgh to advance Trogenix’s novel glioblastoma programme.
November 1, 2024

World-leading experts in gene therapy and brain cancer treatment convene in Edinburgh to advance Trogenix’s novel glioblastoma programme.

Trogenix recently hosted a landmark workshop at The Royal College of Surgeons in Edinburgh, uniting pioneering experts in neurosurgery, gene therapy, and oncology to advance…
Read More
Trogenix awarded Innovate UK grant to advance innovative viral immunotherapy platform for treating cancers with significant unmet medical need.
January 15, 2024

Trogenix awarded Innovate UK grant to advance innovative viral immunotherapy platform for treating cancers with significant unmet medical need.

Grant will accelerate development and evaluate Trogenix’s SSE technology in liver hepatocellular carcinoma and colorectal cancer liver metastases Edinburgh, UK, January 2024 - Trogenix Ltd…
Read More
Trogenix raises £70M series A for glioblastoma gene therapy trial
October 6, 2025

Trogenix raises £70M series A for glioblastoma gene therapy trial

Newco Trogenix Ltd. has emerged from incubation and raised £70 million (US$94.1 million) in a series A, as it prepares the ground for a U.S/U.K.…
Read More
Scottish biotech Trogenix raises $95M as brain cancer program nears clinic
October 5, 2025

Scottish biotech Trogenix raises $95M as brain cancer program nears clinic

Less than a year after leaving stealth mode, Trogenix has raised $95 million in a Series A round aimed at advancing its “Trojan horse” approach…
Read More
Harnessing heterogeneity to treat cancer patients
July 25, 2025

Harnessing heterogeneity to treat cancer patients

Cancer is no longer seen as a simple disease of unchecked cell growth, but as a complex, adaptive ecosystem shaped by genetic mutations, immune evasion,…
Read More
BiotechTV Tour of Scotland
March 14, 2025

BiotechTV Tour of Scotland

Edinburgh-based Trogenix is developing an AAV based gene therapy platform for cancer that is designed to deliver combination immune payloads to the tumour Amy Brown…
Read More
Trogenix unveils odyssey to find one-time tumor drugs with ‘unprecedented selectivity’.
November 18, 2024

Trogenix unveils odyssey to find one-time tumor drugs with ‘unprecedented selectivity’.

Trogenix comes out of stealth, unveiling its innovative Synthetic Super-Enhancers (SSE) platform, Odysseus, to develop highly selective, one-time cancer treatments. Equipped with £15 million ($19…
Read More
Scottish biotech debuts with ‘Trojan horse’ platform for cancer
November 18, 2024

Scottish biotech debuts with ‘Trojan horse’ platform for cancer

Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate targeting an aggressive type of brain…
Read More
JP Morgan Annual Healthcare Conference 2026, San Francisco
October 21, 2025

JP Morgan Annual Healthcare Conference 2026, San Francisco

January 12-15, 2026, San Francisco.
Read More
Jefferies Healthcare Global Healthcare Conference 2025 in London
October 18, 2025

Jefferies Healthcare Global Healthcare Conference 2025 in London

November 17-20, 2025, London, UK
Read More
ICR Healthcare and Sponsors Annual Healthcare Conference 2025
October 17, 2025

ICR Healthcare and Sponsors Annual Healthcare Conference 2025

November 17, 2025, London.
Read More
2025 WFNOS & SNO Annual Meeting, Honolulu
October 17, 2025

2025 WFNOS & SNO Annual Meeting, Honolulu

19 November 2025, Honolulu.
Read More
Bio-Europe 2025
October 15, 2025

Bio-Europe 2025

November 3-5 Vienna Congress and Convention Center, Vienna, Austria
Read More